Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis

Margaux Lelong; Jean-Luc Raoul; Yann Touchefeu; Jean-Marie Berthelot; Paul Arnolfo; Tamara Matysiak-Budnik; Hélène Senellart

doi:10.1002/ccr3.6718

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis

Clin Case Rep. 2022 Dec 12;10(12):e6718. doi: 10.1002/ccr3.6718. eCollection 2022 Dec.

Authors

Margaux Lelong¹, Jean-Luc Raoul¹, Yann Touchefeu², Jean-Marie Berthelot³, Paul Arnolfo³, Tamara Matysiak-Budnik², Hélène Senellart¹

Affiliations

¹ Department of Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France.
² Department of Gastroenterology, (IMAD) University Hospital Nantes France.
³ Department of Rhumatology University Hospital Nantes France.

Abstract

This 38-year-old man has a familial BRCA2 mutation. He presented with skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum; a biopsy of a liver metastase revealed acinar cell carcinoma of the pancreas. After FOLFIRINOX, olaparib was initiated, and 24 months after, the patient was PS 0 and asymptomatic.

Keywords: BRCA mutation; lipase; long survival; pancreatic acinar cell cancer; panniculitis.

Publication types

Case Reports